Literature DB >> 21187509

Combined chemoradiotherapy for early glottic cancer in clinical practice in Japan: analysis of 10 institutions.

Yoshiyuki Itoh1, Naoki Hirasawa, Shinji Naganawa, Shunichi Ishihara, Kazunori Suzuki, Kazuyuki Koyama, Takayuki Murao, Akiko Asano, Yoshito Nomoto, Yoshimi Horikawa, Masahiro Sasaoka, Yasunori Obata.   

Abstract

AIM: To conduct a retrospective analysis regarding treatment strategies for early glottic cancer (GC) at ten institutions. PATIENTS AND METHODS: A questionnaire-based survey was used to obtain personal and medical information on patients who started radiation therapy for T1 or T2 GC between January 2000 and December 2005.
RESULTS: A total of 279 patients were registered for the survey, of whom 124 patients were classified as T1a, with 65 patients as T1b and 87 patients as T2. The rates of chemoradiotherapy for T1a, T1b and T2 were 24%, 23% and 60%, respectively. A comparison of results for academic and non-academic hospitals showed statistically different rates of combination therapy for T1a (6.9% vs. 39.3%, respectively; p<0.001) and T1b (11.4% vs. 36.6%, respectively; p<0.05) but not for T2 (70.0% vs. 54.4%, respectively; p = 0.158).
CONCLUSION: In clinical practice, combined chemoradiotherapy was performed for early GC at most institutions in Tokai District, Japan.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187509

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  Proposal for personalized treatment of early glottic cancer with radiation therapy.

Authors:  Yoshiyuki Itoh; Tamami Ono
Journal:  Nagoya J Med Sci       Date:  2021-11       Impact factor: 1.131

2.  Multi-institutional analysis of early glottic cancer from 2000 to 2005.

Authors:  Naoki Hirasawa; Yoshiyuki Itoh; Shinji Naganawa; Shunichi Ishihara; Kazunori Suzuki; Kazuyuki Koyama; Takayuki Murao; Akiko Asano; Yoshihito Nomoto; Yoshimi Horikawa; Masahiro Sasaoka; Yasunori Obata
Journal:  Radiat Oncol       Date:  2012-08-01       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.